2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
10:30 a.m. - 12:00 p.m.
MCCNO - New Orleans Theatre B
Treatment Considerations, Combination Therapy, Therapy Sequence, Biological Therapies, Bispecific Antibody Therapy, Immunotherapy, Adverse Events, Diseases, Lymphoid Malignancies, Lymphomas, Non-Hodgkin Lymphoma, B Cell Lymphoma, Indolent Lymphoma, Research, Clinical Research, Clinical Trials, Study Population, Human, Adult, Elderly
PAPER

783 Phase II trial of loncastuximab tesirine (WM-NET1 trial) in patients with relapsed/refractory and high-risk Waldenström macroglobulinemia

Shayna Sarosiek, MD, Mary Kwok, MD2, Prashant Kapoor, MD3, Camille Edwards, MD4, Tarek Mouhieddine, MD5, Hannah Chory, NP6, Nina Budano7, Julia Nguyen8, Alexandra usher, MD9, Kirsten Meid, MPH10, Courtney Boyajian11, Steven Treon, MD, PhD12, Jorge J Castillo, MD13
1 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
2 Fred Hutch Cancer Center, Seattle, Washington, United States
3 Mayo Clinic, Rochester, Minnesota, United States
4 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
5 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
6 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
7 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
8 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
9 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
10 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
11 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
12 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
13 Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Introduction: Waldenström macroglobulinemia (WM) is an indolent, incurable lymphoma that often requires multiple lines of therapy, with progressively shorter durations of disease control after each subsequent treatment. CXCR4 mutations (CXCR4MUT) or TP53 alterations (TP53ALT) occur in approximately 30-40% and 5-15% of patients, respectively, and can impact treatment response. CXCR4 mutations are associated with delayed and less profound responses to BTK inhibitors, while TP53 alterations are also associated with reduced response depth and considered to be a high-risk mutation. Additional effective therapies for WM are necessary, particularly for those patients with high-risk or multiply relapsed disease. Loncastuximab tesirine is a humanized IgG1 anti-CD19 antibody-drug conjugate that is FDA approved for the treatment of relapsed large B-cell lymphoma. We hypothesized that loncastuximab tesirine would be effective in WM based on the CD19 expression of the malignant lymphoplasmacytic cells in WM.

Methods: We initiated a prospective, single-arm phase II study (NCT05190705) of loncastuximab tesirine in symptomatic patients with relapsed and/or refractory WM (RRWM). Treatment with single agent loncastuximab tesirine was administered at 150 ug/kg in Cycles 1-2 and 75 ug/kg in Cycles 3-6. Each cycle was 28 days. Dexamethasone 4 mg BID was given the day before, of, and after treatment. The primary outcome measure of this study was attainment of very good partial response (VGPR) or complete response (CR) as per the IWWM-11 criteria. The accrual goal of this trial was 20 patients, based on an alternative VGPR/CR rate ≥40% versus a null of ≤10%, with a double-sided alpha of 0.037 and a power of 87%. The study would meet its endpoint if ≥6 patients attained a VGPR/CR. This study has completed enrollment.

Results: Between May 2022 and April 2026, 20 patients with RRWM were enrolled. Median age was 72 years (range, 53-81) and 13 (65%) were male. Median prior number of therapies was 4 (range, 2-10). Median baseline hemoglobin was 9.2 g/dL (range, 8-13.1), serum IgM was 2056 mg/dL (range, 144-5955), and bone marrow involvement was 50% (range, <5-90). Seven patients have extramedullary disease (4 splenomegaly, 4 adenopathy). Nineteen (95%) had MYD88 mutations; 13/19 patients (68%) had a CXCR4 mutation, and 12 (60%) had a TP53 alteration, including 3 patients who had multiple TP53 mutations (2 patients had 2 and 1 patient had 3 TP53 mutations. Nineteen patients have completed treatment, and 1 patient remains on therapy. No tumor lysis syndrome, IgM flare, or infusion reactions were observed. Treatment was stopped prior to 6 cycles in 6 patients due to asymptomatic GGT elevation (n=2), prolonged cytopenias (n=2), patient decision (n=1), and rash (n=1).

With a median follow-up of 19 months (95% CI 9-23), CR was attained in 2 (10%), VGPR in 10 (50%), partial response (PR) in 4 (20%), minor response in 1 (5%), and stable disease in 2 (10%) patients according to IWWM-11 criteria. One patient had a normal serum IgM at baseline but had reduction in marrow involvement from 50% to 10% and hemoglobin improvement from 7.8 g/dL to 11.6 g/dL consistent with a PR. Based on this, the overall response rate (ORR) was 90%, with a VGPR/CR rate of 60%. Median time to minor response was 1.8 months (95% CI 0.5-1.9), to major response was 2 months (95% CI 1.8-2.8), and to VGPR was 5.8 months (95% CI 3.4-19). At 18 months, the PFS and OS rates were 57% (95% CI 27-79) and 77% (95% CI 43-92), respectively. There were 4 deaths; 2 related to WM progression, 1 due to histologic transformation, and 1 due to intracranial hemorrhage (unrelated to treatment).

The most common grade ≥3 adverse events were reversible neutropenia (70% of patients, 6 grade 4 events), anemia (50%, 1 grade 4 event), thrombocytopenia (35%, 6 grade 4 events), infections (30%, 1 grade 4 event), abnormal liver function tests (15%, 1 grade 4 event), and febrile neutropenia (10%, 1 grade 4 event).

Conclusion: Loncastuximab tesirine demonstrates a high ORR in heavily pre-treated patients with RRWM, despite the presence of high-risk mutations, including 60% of patients with TP53ALT. Notable, is the rapid median time to major response of 2 months and the depth of response, with a VGPR/CR rate of 60%. The most common toxicity was reversible cytopenias. This trial supports the use of loncastuximab tesirine as a novel time-limited therapy for patients with RRWM, including those with high-risk disease.

Shayna Sarosiek, MD: ADC Therapeutics - Research Funding; BeOne - Research Funding; Sobi - Research Funding; AstraZeneca - Research Funding; BeOne - Consultancy (Includes expert testimony); Sobi - Consultancy (Includes expert testimony); AstraZeneca - Consultancy (Includes expert testimony); ADC Therapeutics - Consultancy (Includes expert testimony)